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AbsTrACT
Objectives Rotator cuff- related shoulder pain (RCRSP) 
is a common upper limb complaint. It has been suggested 
that this condition is more common among people with 
cardiometabolic risk factors. This systematic review has 
synthesised evidence from case–control, cross- sectional 
and cohort studies on the association between metabolic 
syndrome (MetS) and RCRSP.
Design and data sources Five medical databases 
(MEDLINE, EMBASE, SCOPUS, CINAHL and AMED) and 
reference checking methods were used to identify all 
relevant English articles that considered MetS and RCRSP. 
Studies were appraised using the Newcastle- Ottawa Scale 
(NOS). Two reviewers performed critical appraisal and data 
extraction. Narrative synthesis was performed via content 
analysis of statistically significant associations.
results Three cross- sectional, two case–control and 
one cohort study met the inclusion criteria, providing a 
total of 1187 individuals with RCRSP. Heterogeneity in 
methodology and RCRSP or MetS definition precluded a 
meaningful meta- analysis. Four of the included studies 
identified associations between the prevalence of MetS 
and RCRSP. Studies consistently identified independent 
cardiometabolic risk factors associated with RCRSP. All 
studies were level III evidence.
summary and conclusion The low- moderate quality 
evidence included in this review suggests an association 
between MetS and RCRSP. Most studies demonstrated 
moderate quality on appraisal. The direction of association 
and cardiometabolic factors influencing should be 
investigated by longitudinal and treatment studies. These 
preliminary conclusions and clinical utility should be 
treated with caution due to limitations of the evidence 
base.
InTrODuCTIOn
Metabolic syndrome (MetS) is a complex 
disorder with high socioeconomic cost and 
mortality.1 2 It is a cluster of interconnected 
physiological, biochemical and clinical 
factors that is associated with cardiovascular 
disease (CVD) and type II diabetes mellitus 
(DM) risk.3 MetS has been associated with 
depression,4 cancer,5 health- related quality 
of life6 and all- cause mortality.7 MetS has 
five primarily components—central obesity, 
elevated triglycerides, hypertension, low high- 
density lipoprotein cholesterol (HDL- C) and 
elevated fasting glucose. This presentation is a 
manifestation of underlying cellular dysfunc-
tion, systemic inflammation and oxidative 
stress.8–13
Chronic low- grade systemic inflamma-
tion is associated with MetS risk factors 
including, hypertension, type II DM, obesity 
and dyslipidaemia.8 14–16 Systemic low- 
grade inflammation has key differences to a 
classic inflammatory response.17 Specifically, 
What is already known on this topic
 ► The prevalence of metabolic syndrome (MetS) is re-
ported to be 23%–46% in the general population.
 ► MetS has been associated with depression, cancer 
risk, low health- related quality of life, musculoskele-
tal pain (low back, neck and knee osteoarthritis) and 
all- cause mortality.
 ► Adipose tissue secretes a variety of bioactive mol-
ecules that individually or collectively suppress or 
enhance inflammation.
What this study adds
 ► There is low- moderate quality evidence for an asso-
ciation between MetS and rotator cuff- related shoul-
der pain (RCRSP).
 ► While causality has not been established, associa-
tions between low- grade inflammatory biomarkers 
and RCRSP have been demonstrated in two included 
studies.
 ► It remains to be investigated if the impact of MetS 
exceeds the sum of all its individual risk factors 
(central obesity, dyslipidaemia, hypertension and 
insulin resistance).
 ► People with MetS are potentially at higher risk of 
shoulder pain, rotator cuff tears and more severe 
rotator cuff tears.
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low- grade systemic inflammation is characterised by 
subtly elevated acute phase proteins and elevated levels 
of active inflammatory cytokines in tissues,14 18–20 with 
very low presence of neutrophils associated with acute 
inflammation.21
Excess adiposity is central to MetS. Diagnostic criteria 
typically mandate the presence of excess adiposity plus 
two of the other components (elevated triglycerides, 
hypertension, low HDL- C and elevated fasting glucose).22 
Adipose tissue is metabolically active and secretes proin-
flammatory cytokines and proteinoids, which individually 
or collectively interact with various biological processes 
that suppress or enhance inflammation.23–25 This contrib-
utes to the development of many systemic complications, 
including abnormal insulin action.12 26 27 Free fatty acid 
mobilisation is accelerated in the presence of insulin 
resistance leading to increased glucose production and 
dyslipidaemia, which perpetuates the low- grade systemic 
inflammation.8
Concordant with the rise in MetS, there is a global 
increase in the prevalence of musculoskeletal (MSK) 
diseases and disorders.28 Cardiometabolic risk factors and 
MSK pain are common comorbidities that feasibly share 
similar aetiology.29 A recent systematic review identified a 
relationship between MetS and Achilles tendinopathy.30 
Furthermore, MetS is more prevalent in people with neck 
pain,31 low back pain32 33 and knee osteoarthritis.34 One 
study showed that MetS was not associated with adhesive 
capsulitis, although associations with type II DM and 
hypertension were identified.35
Shoulder pain is a common MSK complaint in clinical 
practice with point prevalence ranging between 7% and 
26%.36 37 Symptoms associated with the rotator cuff and 
related tissues have been defined as rotator cuff- related 
shoulder pain (RCRSP).38 There is a growing body of 
research associating RCRSP with cardiometabolic risk 
factors, such as obesity, body mass index (BMI) and body 
fat.39–48 Conversely, other studies have reported no rela-
tionship with obesity and RCRSP.49–52 In a cross- sectional 
study, Miranda et al53 reported no association with obesity; 
however, people with type I DM had increased risk of 
RCRSP (OR 8.8; 95% CI 1.9 to 40.3). A recent meta- 
analysis reported the prevalence of tendinopathy, and 
tendon thickness is increased in people with diabetes.54 
Diabetes is associated with an upregulation of proin-
flammatory cytokines as the anti- inflammatory actions 
of insulin is impaired, inducing deregulation of the 
tendon matrix, which may lead to symptoms and func-
tional impairments of the affected tendon.55 The role of 
dyslipidaemia association is inconsistent with two cohort 
studies and one cross- sectional study reporting elevated 
triglyceride and low HDL- C, impact pain and outcome in 
rotator cuff tears as compared with control groups.47 56 57 
Conversely, Longo et al58 conducted a case–control study 
finding no significant difference between total choles-
terol and triglyceride concentrations in people with 
rotator cuff tears and asymptomatic controls. Overall, 
systemic metabolic stress appears to promote low- grade 
inflammation, altered lipid metabolism and insulin resis-
tance that may be associated with disease risk and/or 
progression of RCRSP.59
As the association between MetS and RCRSP is unclear, 
the aim of this study is to systematically review case- 
control, cross- sectional and cohort studies investigating 
the association between MetS and RCRSP.
MeThODs
This review was conducted according to methodology 
guidelines (Centre for Reviews and Dissemination, 2009), 
and reported in accordance with the Preferred Reporting 
Items for Systematic Review and Meta- Analysis (PRISMA) 
statement.60 The review was based on an a priori protocol, 
which described the procedures that would be followed 
(eg, PICO, comprehensive search strategy and a piloted 
data extraction pro forma).
eligibility criteria
All observational designs such as cross- sectional studies, 
case–control studies and cohort studies were included. 
The inclusion criteria were; (1) human study sample 
comprised of adult participants (>18 years), (2) study 
sample presented with signs and symptoms suggestive 
of RCRSP, (3) radiological findings recorded but not 
considered diagnostic of RCRSP, (4) MetS was recorded 
in medical history or met diagnostic criteria of three 
clinical risk factors and (5) participants recruited from 
specialist clinics were deemed to have accurate diag-
nosis of RCRSP or MetS (ie, based on clinical expertise, 
those participants recruited from a metabolic clinic were 
deemed to have MetS and participants attending an 
orthopaedic clinic for RCRSP).
Studies were excluded where a spinal source of pain 
was likely (eg, manikins indicating symptoms over neck 
and upper back) or the study sample comprised of partic-
ipants with other pathologies (eg, fracture, dislocation, 
osteoarthritis, frozen shoulder, neurological presenta-
tions).
Data sources and search strategy
The search strategy and inclusion criteria were specified 
in advance. Studies were identified by an electronic search 
of MEDLINE, CINAHL, EMBASE, SCOPUS and AMED 
from inception to 20 June 2019. Additionally, reference 
lists of all included manuscripts were searched for rele-
vant studies not identified in search strategy, combined 
with an unpublished (grey) literature search. Studies that 
included symptoms suggestive of RCRSP diagnosis and 
cardiometabolic variables related to MetS criteria were 
sought. Search terms were informed by a feasibility search 
and consultation with two health information librarians 
experienced in systematic review methodology. Example 
of the search terms and keywords used with MEDLINE 
(MeSH terms, Medical Subject Headings) are detailed in 
table 1. Records were imported into referencing software 
(Endnote X7), and duplicates removed. Based on eligi-
bility criteria, the titles and abstracts were independently 
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Table 1 MEDLINE search strategy
Search terms
1. Shoulder pain OR shoulder joint OR shoulder impingement OR 
subacromial pain syndrome* OR rotator cuff OR rotator cuff 
disease OR rotator cuff tear.
2. Subacromial impingement syndrome*.
3. Supraspinatus tend*.
4. Shoulder bursitis*.
5. Shoulder tend*.
6. Painful arc*.
7. S1 OR S2 OR S3 OR S4 OR S5 OR S6.
8. Metabolic OR metabolic syndrome OR metabolic syndrome X 
OR syndrome x OR metabolic syn* OR cardio metabolic syn* OR 
Insulin resistance syndrome*.
9. Obesity OR waist circumference OR central obesity OR intra- 
abdominal fat OR waist circumference OR body mass index OR 
BMI OR visceral obesity OR abdominal obesity OR overweight 
OR adiposity OR waist- to- hip ratio.
10. Glycaemic homeostasis OR fasting glucose OR 
glucose intolerance OR Impaired glucose tolerance 
OR IGT OR plasma insulin OR hyperinsulinemia 
OR IFG OR insulin resistance OR pre diabet* OR 
diabetes OR diabetes mellitus OR DM.
11. Blood pressure OR elevated arterial pressure OR 
hypertension.
12. Dyslipidemia OR hyperlipidemia OR dyslipid* OR 
hyperlipid* OR high density lipoprotein OR HDL* OR 
low density lipoprotein OR LDL* OR triglycerides 
OR total cholesterol OR hypertriglyceridemia.
13. Microalbuminuria OR albumin OR urine albumin.
14. S8 OR S9 OR S10 OR S11 OR S12 OR S13.
15. S7 AND S14.
16. Limit to >18 (adult) and English.
*Truncation command
reviewed by one reviewer (GB) and relevant studies were 
accessed for full text. All potentially relevant studies were 
reviewed to determine final study selection (GB, MM); 
the reasons for exclusion at this stage were documented. 
A third reviewer (JL) was available for consultation and 
consensus.
Data extraction
Data extraction was performed by one reviewer (GB) 
and checked for verification and accuracy by a second 
reviewer (MM) using a predesigned piloted form. Data 
extraction for each study included: study location, study 
design, sample characteristics (age, gender), case defini-
tion and method of diagnosis for RCRSP, definition used 
to classify MetS or cardiometabolic risk factors included 
that met MetS definition within study population. 
Outcomes in terms of OR (unadjusted or adjusted), 95% 
CIs and when available significant p values <0.05 were 
extracted. In circumstances where it was not possible to 
extract these data from the manuscript, corresponding 
authors were contacted to seek clarification or request 
individual patient data.
Data analysis
The included studies were assessed by two reviewers (GB, 
MM) through examination of the data extraction table. 
This demonstrated significant heterogeneity of subject 
characteristics (definition of RCRSP), cointerventions, 
exposure and criteria for diagnosing MetS, subsequently 
meta- analysis was precluded. A narrative synthesis with 
emphasis on study design and quality was undertaken as 
per the method described by Popay et al. Oxford Centre 
for Evidence- based Medicine (OCEBM) levels of evidence 
was used as guidance to evaluate selected articles.61
Quality appraisal
Quality of the included studies was evaluated using 
the Newcastle- Ottawa Scale (NOS) for cross- sectional, 
case–control and cohort studies.62 This appraisal tool is 
recommended by the Cochrane Handbook for System-
atic Reviews of Interventions.63 The NOS checklist 
assesses quality of articles across three domains: selec-
tion of the study groups; comparability of the groups 
and control for cofounding factors; and exposure. The 
minimum and maximum scores available is 0 and 9, 
respectively. The studies with score ≥6; ≥3 score <6; and 
score <3 were considered high quality, moderate quality 
and low quality, respectively.64 Two reviewers (GB, MM) 
independently examined the studies for risk of bias and 
internal validity (table 2). In order to assess interobserver 
agreement of the risk of bias, the kappa coefficient (κ) 
was used.65
resulTs
search strategy
Figure 1 shows search and study selection process. After 
exclusions, 36 studies required the full text to be assessed. 
Out of these, 30 studies were excluded (23 studies had 
incomplete cardiometabolic details available to establish 
a MetS definition, 5 studies had no shoulder pain data 
and 2 studies did not meet participant criteria), resulting 
in 6 studies42 43 55 66–68 for inclusion in this review.
study characteristics
Table 3 presents a summary of characteristics and findings 
of each included study. Within the construct of RCRSP; 
four studies examined people diagnosed with symptom-
atic rotator cuff tendinopathy and two studies examined 
people with symptomatic rotator cuff tears (partial 
and full thickness). Four studies were cross- sectional, 
one case controlled and one retrospective cohort. The 
total number of individuals across the studies was 8259 
(mean age 50.9 years), of which 1187 were people expe-
riencing RCRSP. Five studies recruited participants from 
health centres or hospitals.42 43 55 67 68 Applegate et al66 
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Figure 1 PRISMA flow diagram showing study selection 
process.60 PRISMA, Preferred Reporting Items for Systematic 
Review and Meta- Analysis.
recruited participants from 17 diverse production facili-
ties, including food processing, manufacturing, assembly 
lines and office jobs.
Quality assessment
The six included studies were clinical human reports and 
considered level III evidence in line with OCBEM guid-
ance. The results of the quality appraisal are shown in 
table 2. According to our definition, 1/6 of the studies 
were good quality, 4/6 medium quality and 1/6 of low 
quality. This was due to a number of common deficien-
cies in the methodological quality of these studies. With 
the exception of one study,67 the others did not report a 
study protocol. Response rates from preliminary sampled 
subjects were not reported in three studies,42 43 66 thus 
substantial selection bias may have occurred. Studies 
tended to report variables for all their stated aims but 
did not specify which aims were determined in advance 
of conducting the study. Study quality as assessed by the 
NOS varied considerably across the studies ranging from 
1/9 to 9/9, the main issues being lack of adequate diag-
nosis, definition of controls and lack of adjustment for 
potential cofounders (table 2). Interobserver agreement 
regarding the risk of bias was considered ‘substantial’ 
(κ=0.76) according to the Viera and Garrett69 kappa 
interpretation model.
rCrsP diagnosis classification
The six studies had inconsistent diagnostic classification 
of RCRSP through a mix of self- reported symptoms, 
clinical findings and radiological imaging (table 3). For 
example, one study confirmed RCRSP as pain during 
functional activities (range of motion) and sonographic 
diagnosis of a partial or full thickness rotator cuff tear.55 
Conversely, one study utilised the international classifi-
cation of disease (ICD) 10 code70 and one other study 
utilised radiography to differentiate primary or centred 
osteoarthritis.67
Mets diagnosis classification
MetS diagnosis was clearly defined within two studies 
using the National Cholesterol Education Programme 
Adult Treatment Panel III (NCEP ATP III).42 43 The 
remaining studies did not state which definition criteria 
was used (table 3). Within data extraction all studies met 
a definition set by many international expert groups, 
such as the WHO and the International Diabetes Feder-
ation (IDF). There is no currently agreed diagnostic 
consensus.8 The variance is attributed to the focus of 
each definition, from the obesity- centric IDF to a gluco-
centric WHO definition and the collection of statistically 
elevated CVD risk factor by the NCEP ATP III.
Analysis
Of the studies included, four studies reported a positive 
association between MetS and shoulder pain. Applegate 
et al66 reported an adjusted OR for glenohumeral joint 
pain among people with the highest CVD risk score 
(18+), scaled in accordance with a modified Framingham 
Heart Study’s risk assessment,71 namely, hypertension, 
dyslipidaemia and diabetes of 4.55 (95% CI 1.99 to 10.40, 
p<0.001). Similarly, the adjusted OR for RC tendinopathy 
in those with the highest CVD risk score was 5.97 (95% CI 
2.12 to 16.83, p<0.008). Djerbi et al67 reported an unad-
justed OR for symptomatic rotator cuff tears (SCOI 1–3) 
of OR 2.55 (95% CI 1.4 to 4.58, p=0.0017) for obesity, 
2.04 (95% CI 1.18 to 3.52, p=0.0102) for systolic BP and 
7.69 (95% CI 3.35 to 17.25, p<0.0001) for dyslipidaemia. 
Higher grade tears (SCOI 4) were also associated with 
obesity (OR 2.105, p=0.0117), systolic BP (OR 4.311, 
p<0.0001) and dyslipidaemia (OR 2.867, p=0.0004). 
Although, when adjusted, only dyslipidaemia (OR 4.920; 
95% CI 2.046 to 11.834, p=0.0004) and systolic BP (OR 
3.215; 95% CI 1.67 to 6.19, p=0.0005) were associated. 
Rechardt et al42 reported an adjusted OR for unilateral 
glenohumeral joint pain over a 3 month period of 1.7 
(95% CI 1.3 to 2.1) for MetS (NCEP ATP II definition) 
in males. This study found MetS was not associated with 
rotator cuff tendinopathy (OR 0.7; 95% CI 0.4 to 1.1). 
Juge et al reported a significant difference in the propor-
tion of people with established MetS criteria (obesity, DM, 
dyslipidaemia, hypertension) between RCRSP (6.5%) 
and those with osteoarthritis (0%, p=0.03). Two studies 
reported no association between MetS and RCRSP. Abate 
et al55 reported no significant difference in rotator cuff 
tear prevalence in people with cardiometabolic risk 
factors meeting MetS criteria. Although, this study did 
report positive power of the predictor coefficient (β) for 
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cardiometabolic risk factors of BMI (β=0.32, p=0.047) 
and DM (β=1.01, p=0.029).55 Indicating higher values of 
BMI and DM are related to a higher probability to detect 
rotator cuff tears. Similarly, Rechardt et al43 reported 
no association with pain intensity in RCRSP and MetS, 
however, did report central obesity (waist- to- hip ratio 
>0.9, OR 3.3; 95% CI 1.3 to 8.6; waist circumference OR 
3.2; 95% CI 1.4 to 7.4) and dyslipidaemia (OR 2.7; 95% 
CI 1.2 to 6.3) were positively associated when adjusting 
for age and sex.
DIsCussIOn
The low- moderate quality evidence included in this 
review suggests an association between MetS and RCRSP. 
From the six studies included (one good quality, one low 
quality and four medium quality) it appears there is an 
association between MetS (and its constituent factors) 
and RCRSP. Two medium quality studies reported no 
association with MetS, but reported associations between 
cardiometabolic risk factors (BMI, DM and dyslipidaemia) 
and painful shoulders with identifiable unilateral rotator 
cuff tears and with RCRSP. In addition, populations with 
independent cardiometabolic risk factors associated with 
RCRSP were identified across all studies (table 3); age 
>45 years, obesity (notably central adiposity), DM, hyper-
tension and dyslipidaemia.
Obesity, DM, hypertension and dyslipidaemia are 
components of MetS and are also interrelated. It is there-
fore difficult to separate the individual versus combined 
effect of these factors. Previous research on RCRSP has 
identified relationships with independent cardiometabolic 
risk factors including adiposity,41 45 46 diabetes,54 72 dyslip-
idaemia57 and hypertension.73 For example, an 11- year 
nation- wide, longitudinal follow- up study of 498 678 people 
of whom 26 664 developed RCRSP showed a diagnosis of 
diabetes had a hazard ratio (HR) of 1.47 (95% CI 1.41 to 
1.54; p<0.0001) for RCRSP and hyperlipidaemia had a HR 
of 1.48 (95% CI 1.42 to 1.55; p<0.0001) for RCRSP.74 Simi-
larly, a 4- year, longitudinal follow- up of 10 044 people with 
clustered back, neck and/or shoulder pain showing a diag-
nosis of diabetes had a relative risk of 1.64 (95% CI 1.23 to 
2.18) for shoulder pain in males and hyperlipidaemia had a 
relative risk of 1.19 (95% CI 0.98 to 1.44) for shoulder pain 
in males.75 Furthermore, a large case–control study of 5000 
patients with RCRSP identified that increased BMI (BMI 
between 25.1 and 30) was independently associated (OR 
1.15; 95% CI 1.02 to 1.31) with RCRSP.76 Given these asso-
ciations, RCRSP and cardiometabolic risk factors may share 
a common aetiology. As yet it is unclear whether the impact 
of MetS of RCRSP exceeds the sum of all its individual 
factors. More studies are required to assess the indepen-
dent contribution of MetS; however, the above aggregative 
risk factors suggest MetS may play a role in RCRSP.
The postulated pathophysiological mechanisms 
cannot be fully understood on the basis of available 
studies. While causality has not been established, associ-
ations between low- grade inflammatory biomarkers and 
RCRSP have been shown. Excess central adiposity is key 
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constituent of MetS and adipose tissue is a rich source 
of circulating proinflammatory cytokines; collectively 
referred to as adipocytokines, including, tumour necrosis 
factor alpha (TNF-α), IL-1β, IL-1, IL-6, adiponectin, 
leptin and restinin. Increased cytokine expression 
has been observed in the subacromial bursa (IL-1 and 
IL-6) and partial thickness rotator cuff tear tissue (IL-6) 
from subjects undergoing rotator cuff surgery.77–79 Also, 
increased expression serum levels of TNF-α within 
subacromial bursa specimens have been retrieved during 
symptomatic rotator cuff tendon surgery.80 In parallel, 
reduced level of IL-10 is detected in patients with obesity, 
dyslipidaemia and insulin resistance.81 IL-10 is an anti- 
inflammatory cytokine that modulates the immune 
system by antagonising the activities of proinflammatory 
cytokines.12 It is possible that the resultant increased 
proinflammatory adipocytokine expression and anti- 
inflammatory adipocytokine suppression is a risk factor 
for developing RCRSP.43
Dysregulation of adipokines resulting from central 
obesity contributes to DM.82 Type I and type II DM has 
been associated with increased risk of chronic RCRSP.23 54 
Hyperglycaemia has vasodilatory and proinflammatory 
actions mediated by cytokine suppression. 83 Increased 
glucose availability had direct effects on tendons of the 
rotator cuff and can alter the physiological behaviour 
of tendons.84 The low- grade, subclinical, but persistent 
inflammation in DM has been shown to affect collagen 
crosslinking, proteoglycan content, cytokine activity, 
which can lead to tendon thickening and matrix degen-
eration.23 54 85
Multifunctional (proinflammatory or anti- 
inflammatory) proteins such as leptin, adiponectin, 
resitin and vistafin have been discovered within the 
adipocytokine family. These are involved with the low- 
grade inflammation encountered in obese and diabetic 
subjects linked to the pathogenesis of MetS.86 87 Little 
is known about their role within MSK disorders. An 
association has been reported between increased proin-
flammatory leptin and pain related to arthrosis of the 
shoulder.88 Decreased anti- inflammatory adiponectin 
levels have been associated to pathological conditions of 
diabetes and MetS89 and found to be lower within the 
synovial fluid of people with shoulder pain.88 Although 
little is known about the role of these proteins they may 
have a role within shoulder pain and metabolic disorders.
There is inconsistency regarding the link between 
hypercholesterolemia and RCRSP. Longo et al58 found no 
association between elevated total cholesterol and rotator 
cuff injury; however, the mean triglyceride concentration 
was below the threshold 1.7 mmol/L for 62.5% (mean 
1.49 mmol/L) to meet the diagnostic criteria required 
for MetS. In contrast, Abboud et al57 did find a correla-
tion between rotator cuff tears and increased cholesterol 
levels, specifically with elevated low- density lipoprotein 
cholesterol (LDL- C) and low HDL- C levels. The mech-
anism by which dyslipidaemia affects shoulder pain is 
also unknown. It is hypothesised that due to catabolism 
of HDL- C increased LDL- C could initiate and maintain, 
low- grade persistent inflammation within the rotator cuff 
tendon, as shown in vivo studies on rotator cuff tendon in 
mice.23 90 There may also be direct cholesterol deposition 
within tendon.91–95 Dyslipidaemia is a known precursor 
for hypertension and CVD.96 This may also contribute 
to RCRSP, as subsequent endothelial damage caused 
by hypertension and deregulated lipid metabolism has 
been associated with tissues damage in tendons.97 This 
is supported by Gumina et al73 who noted hypertension 
was associated with a twofold increase of a large rotator 
cuff tear (OR 2.09; 95% CI 1.39 to 3.16) and fourfold 
increase of massive rotator cuff tear (OR 4.30; 95% CI 
2.44 to 7.58). However, the study was not able to adjust 
for the range of antihypertensive medication drugs, thus 
not possible to define this influence on tear dimensions. 
This tissue damage in the presence of hypertension has 
been linked to hypovascularity and hypoxia, ultimately 
depriving tissues of appropriate nutrient exchange.98 
This triggered deregulation of the tendon matrix may 
lead to symptoms and functional impairments of the 
affected tendon in RCRSP.55
These findings should be viewed with some caution as 
biological measures do not work in isolation but rather 
interact with an array of complex systems and consid-
eration of a composite of measures reflecting system 
functioning.99 No study has reported biomarkers that 
might represent potential mediators between MetS and 
RCRSP.100 Furthermore, the evidence supporting the 
influence of postulated MetS- induced inflammatory 
biomarkers and its association with symptoms in either 
the acute or chronic stage of RCRSP is lacking.100 RCRSP 
has a multifactorial aetiology. It is recommended these 
findings be considered within a wider management of 
RCRSP including recognition of increased excitability of 
the peripheral and central neuraxis or decreased inhi-
bition,101 psychosocial and work- related factors.101–103 
Clinicians should, however, remain cognisant of 
cardiometabolic status throughout rehabilitation, partic-
ularly in respect to how metabolic stress may precipitate 
low- grade systemic inflammation17 and it’s purported 
deleterious impact in RCRSP.
limitations
This review summarises the potential association between 
MetS and RCRSP, the basis of which are limited to the 
outcomes used by the original studies. With no clear 
consensus across the included literature, the clinical 
utility of identifying MetS in patients with RCRSP may be 
questioned.
The diagnostic criteria for RCRSP varied considerably 
across studies. Including a combination of participant self- 
reported symptoms, clinical assessment testing and varied 
radiological imaging techniques, which may impact the 
reliability and external validity of findings. Furthermore, 
four studies included an assembled MetS profile, with 
only two studies stated predetermined criteria used to 
define MetS. Currently, no universally agreed diagnostic 
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criteria for MetS or RCRSP exists, which can be used as 
a comparative within both clinical and research fields. It 
is recognised that the classification of the NOS scoring 
criteria (‘high’, ‘moderate’ and ‘low’) adopted in this 
review is novel and has limited evidence. However, this 
method of ‘grading’ can provide context when applying 
our findings to future research and clinical practice. The 
standardisation of MetS and RCRSP diagnosis criteria is 
essential for clinicians and researchers alike to generate 
research. This allows results to be compared and pooled 
to make meaningful conclusions regarding metabolic 
factors in MSK shoulder pain. It is important to consider 
methodological quality of the included studies as the 
majority were cross- sectional in which selection bias 
cannot be avoided. For example, associations maybe 
accentuated because the investigators accessed pools of 
RCRSP patients from specialist health centres with access 
to pools of MetS subjects. Furthermore, it cannot be 
determined that exposure predetermined disease since 
data were ascertained at the same time. Overall, the 
available evidence was of relatively low- moderate quality, 
specifically, all studies were of level III evidence. With 
evident methodological concerns, as described above, it 
is likely the findings from this review will evolve as high- 
quality studies become available.
Future research
Questions remain on the direction of RCRSP association 
and therefore on the possibility of an effective manage-
ment of MetS and vice versa. Initially, researchers should 
address the need for harmonising the diagnostic criteria 
for MetS, including the definition of optimal meta-
bolic biomarkers and normative age- related values. The 
consistency of RCRSP diagnostic criteria also needs to be 
established in future studies; this will enhance the anal-
ysis of results when this review is updated. Cross- sectional 
design limits causal inference. Well- controlled prospective 
large- scale studies will be an important next step to exam-
ining the relationship between MetS and RCRSP. This 
should include examining changes in pain, cofounders, 
health behaviours and biological measures in order to 
better appreciate potential causal direction. When suffi-
cient homogenous representative samples are available, 
a repeated systematic review with meta- analysis should be 
considered to pool data of an adequate sample size to 
quantify the strength of the association. This may then 
allow investigations into the effects comorbidity manage-
ment could influence RCRSP associated symptoms and 
through which biological pathway they act. Furthermore, 
this may propose a subcategory of metabolic shoulder 
pain introducing new ideas of management and prog-
nosis.
COnClusIOns
The results of this review suggest a positive association 
between MetS and RCRSP in six low- moderate quality 
studies. Specifically, patients with MetS are potentially 
at higher risk of shoulder pain, rotator cuff tears and 
more severe rotator cuff tears. While causality has not 
been established, two studies included in this review have 
associations between low- grade inflammatory biomarkers 
and RCRSP.
These preliminary conclusions should be treated with 
caution due to significant methodological limitations 
and concerns regarding their validity. It is likely that 
future high- quality primary studies may challenge these 
preliminary conclusions.
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